Incidence and prevalence of immune thrombocytopenia under the copayment waiver policy for pediatric patients in Korea: Data from the National Health Claims Database
- PMID: 33593162
- DOI: 10.1177/0961203321995247
Incidence and prevalence of immune thrombocytopenia under the copayment waiver policy for pediatric patients in Korea: Data from the National Health Claims Database
Abstract
The purpose of this study was to investigate the epidemiology of immune thrombocytopenia (ITP) under the copayment waiver policy for pediatric patients in Korea. The data were collected from the National Health Insurance Claims Database of Korea. ITP was identified based on the diagnostic code D69.38 from the Korean Standard Classification of Diseases. Patients between one and 18 years old, who had at least one health insurance claim for ITP as a final diagnosis, from 1 January 2016, to 31 December 2017, were analyzed. Prevalent cases were defined as patients who used, at least one time, any medical services coded as D69.38. Incident cases were defined as patients who did not use D69.38 coded medical services during the prior year and were newly registered in 2017. The prevalence and incidence of ITP were 24.53 and 13.39 per 100,000 persons. The peak rates were observed in 1-year-old patients. The gender-specific prevalence of ITP was significantly higher in one-year-old males than females. According to the change-point analysis, we found that the prevalence and incidence diminished rapidly at the ages of four and three, respectively. This Korean population-based epidemiological study of ITP provided meaningful insights into the current epidemiology of ITP and demonstrated the implications of interpreting epidemiologic studies to reflect age categorizing and health care system characteristics.
Keywords: Incidence; Korea; immune thrombocytopenia; national health insurance data; prevalence.
Similar articles
-
Incidence and Prevalence of Juvenile Systemic Lupus Erythematosus in Korea: Data From the 2017 National Health Claims Database.J Rheumatol. 2021 Feb;48(2):258-261. doi: 10.3899/jrheum.191186. Epub 2020 May 1. J Rheumatol. 2021. PMID: 32358155
-
Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis.J Med Econ. 2020 Feb;23(2):184-192. doi: 10.1080/13696998.2019.1669329. Epub 2019 Oct 9. J Med Econ. 2020. PMID: 31547724
-
Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database.Eur J Haematol. 2017 Oct;99(4):344-349. doi: 10.1111/ejh.12926. Epub 2017 Aug 22. Eur J Haematol. 2017. PMID: 28692146
-
The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review.Eur J Haematol. 2009 Aug;83(2):83-9. doi: 10.1111/j.1600-0609.2009.01247.x. Epub 2009 Feb 23. Eur J Haematol. 2009. PMID: 19245532
-
The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports.Am J Hematol. 2010 Mar;85(3):174-80. doi: 10.1002/ajh.21616. Am J Hematol. 2010. PMID: 20131303 Review.
Cited by
-
Changes in the Incidence of Immune Thrombocytopenia in the Coronavirus Disease 2019 Era: A Nationwide Observational Study in Korea.Risk Manag Healthc Policy. 2023 Apr 10;16:667-676. doi: 10.2147/RMHP.S403196. eCollection 2023. Risk Manag Healthc Policy. 2023. PMID: 37064796 Free PMC article.
-
Management of immune thrombocytopenia: 2022 update of Korean experts recommendations.Blood Res. 2022 Mar 31;57(1):20-28. doi: 10.5045/br.2022.2022043. Blood Res. 2022. PMID: 35342042 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources